> G+ > Orphan Drugs: Commercialization, Clinical and Regulatory Challenges
 

Orphan Drugs: Commercialization, Clinical and Regulatory Challenges

White Paper Published By: G+
G+
Published:  May 17, 2011
Type:  White Paper
Length:  5 pages

The industry’s 70% market share in 2009 for rare and genetically inherited diseases increased from a little over 50% three years earlier. Successfully competing in this space requires different strategies and skills than those necessary for blockbuster drug development.

In this takeaway presented by G+, Gerson Lehrman Group Inc.’s panel of experts discusses the commercial, clinical, and regulatory challenges unique to orphan drug development.



Tags : 
gerson lehrman group, orphan drug, regulatory challenges, drug development, commercialization, clinical